3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
6
Recruiting
5
Terminated
4
Active not recruiting
4
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
20
Magnetic Resonance Spectroscopy
10
Radiotherapy
9
Blood Specimen Collection
8
pembrolizumab
6
Cyclophosphamide
6
Bevacizumab
6
AZD 6244
6
Radiation
5
Specimen Handling
4
vorasidenib
3
fludarabine
3
cemiplimab
3
aflutinib
3
Surgical Procedures, Operative
3
Saline Solution
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Pemetrexed
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
tislelizumab
2
osimertinib
2
naxitamab
2
gallium maltolate
2
fludarabine phosphate
2
dinutuximab
2
Topotecan
2
Standard of Care
2
Spinal Puncture
2
Receptors, Interleukin-8B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
dabrafenib
×
CNS
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled